Biopharma PEG Scientific Inc articles

The recent FDA approval of vepdegestrant (Veppanu™) represents a major milestone for targeted protein degradation, introducing the first approved PROTAC therapy for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. The approval highlights the growing maturity of the PROTAC platform and reinforces the importance of molecular design in next-generation therapeutics.

PROTACs (Proteolysis Targeting Chimeras) differ from conve

Watertown, MA – May 29, 2026 – Biopharma PEG, a manufacturer of polyethylene glycol (PEG) derivatives, offers a comprehensive selection of high-purity (>96%) DSPE-PEG compounds, including DSPE-PEG-Mannose, DSPE-PEG-NH2, DSPE-PEG-MAL, and DSPE-PEG-NHS. These functionalized lipids help biopharmaceutical companies design stable, long-circulating nanocarriers for targeted therapies.

DSPE-PEG is an amphiph

Biopharma PEG will participate in TIDES USA 2026 this May in Boston, where the company will present a range of high-purity PEG derivatives for drug delivery, bioconjugation, and pharmaceutical development.

The event will take place at the Hynes Convention Center, Boston, MA, USA, from May 11–14, 2026. Biopharma PEG will be located at Booth 826, where visitors can l

CAR-T cell therapy has transformed the treatment landscape for hematological cancers, yet its widespread adoption remains limited by the complexity of ex vivo manufacturing. Patient-specific cell collection, genetic modification, and reinfusion introduce high costs, long timelines, and scalability challenges.

To address these barriers, in vivo CAR-T has emerged as a new strategy—engineering T cells directly inside the patient using nucleic acid delivery systems. This approach has

In the fast-evolving field of antibody–drug conjugates (ADCs), linker chemistry plays a decisive role in defining therapeutic performance. The ability to control the drug-to-antibody ratio (DAR), conjugation site, and overall molecular stability directly impacts both efficacy and safety.

Among emerging linker materials, azide-functionalized PEG derivatives have become essential tools for CuAAC (copper-catalyzed) and SPAAC (strain-promoted) click conjugation. These bio-orthogonal

Antibody-drug conjugates (ADCs) combine potent small-molecule drugs with monoclonal antibodies for targeted cancer therapy. A major challenge is loading enough drug onto each antibody without compromising solubility or circulation time. Introducing polyethylene glycol (PEG) linkers between the antibody and drug payload can address this. PEG is hydrophilic, biologically inert, and FDA‐recognized as safe. As a flexible spacer, PEG “shields” the hydrophobic drug, greatly improving

Watertown, MA – March 24, 2025 – Biopharma PEG, a leading supplier of high-quality polyethylene glycol (PEG) derivatives, highlights its innovative product DSPE-PEG-Mannose, an advanced biomedical polymer with significant potential in drug delivery, tumor-targeted therapy, tissue recognition, and adhesion.

Structural Advantages of DSPE-PEG-Mannose

DSPE-PEG-Mannose is composed of three key components that enable its diverse applications:

l DSPE (1,2-Distearoyl-sn-gly

Watertown, MA, July 22, 2024  – Biopharma PEG, a top supplier of PEG derivatives, is excited to introduce its new line of monodispersed PEGs. These specially sized polymers are designed to improve the stability and delivery of proteins and peptides in drugs. They are essential for Antibody-Drug Conjugate (ADC) linkers, Proteolysis Targeting Chimeras (PROTAC) linkers, and PEGylated proteins and peptides.

PEGs as ADC Linkers

PEGs act as a shield around the ADC payload,

Biopharma PEG, a leading innovator in polyethylene glycol (PEG) derivatives, proudly introduces its featured Azide PEG series, which can be used in drug development, click chemistry, ADCs (Antibody Drug Conjugates), PROTACs (Proteolysis Targeting Chimeras), and beyond.

This Azide PEG features monodispersed PEGs such as N3-PEG4-OH, N3-PEG3-COOH, N3-PEG11-NH2, N3-PEG3-NHS ester, 2-((Azido-PEG8-carbamoyl)methoxy)acetic acid,